Table 4 Fine and Gray competing risk survival analyses of boost radiotherapy and cardiovascular disease or ischemic heart disease events
N | Competing risk events N (%) | Competing risk models, sHR (95% CI) * | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Crude | Age 25 | Age 35 | Age 39 | Age 45 | Age 55 | Age 65 | Age 75 | |||
Cardiovascular diseasea | ||||||||||
No boost | 3343 | 268 (8.0) | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] |
Boost | 1917 | 345 (18.0) | 0.4 (0.3–0.6) | 1.5 (0.6–3.6) | 1.3 (0.7–2.5) | 1.2 (0.7–2.1) | 1.1 (0.7–1.8) | 1.0 (0.7–1.3) | 0.9 (0.7–1.1) | 0.7 (0.5–1.1) |
Ischemic heart diseaseb | ||||||||||
No boost | 3343 | 418 (12.5) | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] | 1 [Ref] |
Boost | 1917 | 457 (23.8) | 0.4 (0.2–0.7) | 5.1 (1.2–22.6) | 3.2 (1.04–9.8) | 2.8 (1.002–7.7) | 2.0 (0.9–4.4) | 1.2 (0.7–2.1) | 0.8 (0.5–1.3) | 0.5 (0.2–1.02) |